Plain-English translation of NCT06375187 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new treatment called GC203 TIL, which uses your own immune cells that have been specially engineered in the laboratory to fight cancer. Researchers will take a small sample of tumor tissue from you, grow and strengthen your immune cells in the lab, and then infuse them back into your body to attack the cancer. The study aims to see if this approach is safe and whether it helps shrink tumors in people with advanced cancers that have not responded to standard treatments.
Many patients with advanced solid tumors stop responding to standard cancer treatments like chemotherapy or immunotherapy. This medication represents a newer approach that harnesses your own immune system's power by engineering your cells to be better cancer fighters, potentially offering hope to patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
You will undergo a procedure to have a small sample of your tumor removed so that researchers can extract and engineer your immune cells in the laboratory. After several weeks of preparation, you will receive an injection of these engineered cells back into your body. You will then be monitored closely with blood tests and imaging scans to see how your body responds and whether the treatment shrinks your cancer. The study involves multiple clinic visits and will require you to commit to follow-up appointments and tests over several months.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Shanghai Juncell Therapeutics
Enrollment target
~18 participants
Started
May 2024
Primary completion
November 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Huajun Jin, PhD
Shanghai Juncell Therapeutics
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.